natgillin/translations-raw huggingface dataset:
De øvrige indholdsstoffer i pulveret er polysorbat 80, natriumklorid (se også punkt 2), kalciumklorid-dihydrat, saccharose, Tris-base, Tris-hydroklorid og tri-natriumcitrat-dihydrat.
The other ingredients in the powder are polysorbate 80, sodium chloride (see also section 2), calcium chloride dihydrate, sucrose, Tris base, Tris HCl, Tri-sodium citrate dihydrate.
De øvrige indholdsstoffer i tabletkernen er (se afsnit 2 ”Clopidogrel Teva Pharma B.V. indeholder lactose” og ”Clopidogrel Teva Pharma B.V. indeholder hydrogeneret ricinusolie”): lactosemonohydrat, mikrokrystallinsk cellulose, hydroxypropylcellulose (E463), crospovidon (type A), hydrogeneret ricinusolie og natriumlaurylsulfat, og er i filmovertrækket lactosemonohydrat, hypromellose (E464), titandioxid (E171), macrogol 4000, rød jernoxid (E172), gul jernoxid (E172), indigocarmin (E132).
The other ingredients in the tablet core are (see section 2 ‘Clopidogrel Teva Pharma B.V. contains lactose’ and ‘Clopidogrel Teva Pharma B.V. contains hydrogenated castor oil’) lactose monohydrate, microcrystalline cellulose, hydroxypropylcellulose (E463), crospovidone (type A), hydrogenated castor oil and sodium laurilsulfate, and in the film-coating are lactose monohydrate, hypromellose (E464), titanium dioxide (E171), macrogol 4000, iron oxide red (E172), iron oxide yellow (E172), indigo carmine aluminium lake (E132).
De øvrige indholdstoffer er:
The other ingredients are:
De øvrige indholdstoffer er: (tabletkernen) lactosemonohydrat, hydroxypropylcellulose, crospovidon (type A), silica, kolloid vandfri, mikrokrystallinsk cellulose, magnesiumstearat, (tabletovertrækket) hypromellose, polydextose, glyceroltriacetat, macrogol 8000, titandioxid (E171).
The other ingredients are: (tablet core) lactose monohydrate, Hydroxypropylcellulose, Crospovidone (type A), Silica colloidal anhydrous, Microcrystalline cellulose, Magnesium stearate, (tablet coating) Hypromellose, polydextrose, glycerol triacetate, macrogol 8000, titanium dioxide (E171).
De øvrige indholdstoffer er: mannitol, aspartam (E951), magnesiumstearat, crospovidon type B, lactosemonohydrat, hydroxypropylcellulose, citronsmag (smagsstof(fer), maltodextrin, saccharose, arabisk gummi (E414), glyceryltriacetat (E1518) og alfa-tocopherol (E307).
The other ingredients are Mannitol, Aspartame (E951), Magnesium Stearate, Crospovidone type B, Lactose monohydrate, Hydroxypropylcellulose and Lemon Flavour [flavouring preparation(s), maltodextrin, sucrose, gum arabic (E414), glyceryl triacetate (E1518) and alpha-Tocopherol (E307)].
De øvrige ingredienser til 15 mg er krystallinske maltose, mikrokrystallinsk cellulose, prægelatineret stivelse, croscarmellosenatrium, gul jernoxid (E172) og magnesiumstearat.
The other ingredients for 15 mg are crystalline maltose, microcrystalline cellulose, pregelatinised starch, croscarmellose sodium, iron oxide yellow (E172) and magnesium stearate.
De øvrige ingredienser til 5 mg er krystallinske maltose, mikrokrystallinsk cellulose, prægelatineret stivelse, croscarmellosenatrium, indigo (E132) og magnesiumstearat.
The other ingredients for 5 mg are crystalline maltose, microcrystalline cellulose, pregelatinised starch, croscarmellose sodium, indigo carmine (E132) and magnesium stearate.
De øvrige lægemidler mod hiv skal gives sammen med INTELENCE som anbefalet af barnets læge.
The other HIV medicines used in combination with INTELENCE should be taken by the child as recommended by the child’s doctor.
De øvrige ni dødsfald blandt dem, der blev behandlet med SIRTURO, indtraf efter gennemførelse af behandlingen med dette lægemiddel (interval 86-911 dage efter SIRTURO; median 344 dage).
The other nine deaths among those treated with SIRTURO occurred after completion of treatment with this agent (range 86-911 days post-SIRTURO; median 344 days).
De øvrige patienter blev behandlet med 2.000 eller 2.500 E/m2 administreret intramuskulært eller intravenøst.
The remaining patients were treated with 2000 or 2500 U/m2 administered intramuscularly or intravenously.
De øvrige to tilfælde (dechallenge ukendt) var sammenfaldende med komorbiditeten glaukom.
The other 2 cases, (dechallenge unknown) were confounded by comorbidity of glaucoma.
De, der ikke endnu er blevet indtastede, skal rapporteres i den efterfølgende S- PSUR.
Those which have not yet been entered should be reported in the following S- PSUR.
DE-48159 Münster Tyskland
48159 Münster Germany
De/du kan finde yderligere oplysninger om YTRACIS på Det europæiske Lægemiddelagenturs hjemmeside http://www.ema.europa.eu/.
Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu
Deacetyleringen medieres af carboxylesteraser (dvs. carboxylesterase 1b/c og 2) og kan også medieres af andre hydrolytiske enzymer.
The deacetylation is mediated by carboxyl- esterases (i.e. carboxylesterase 1b/c and 2) and may also be mediated by other hydrolytic enzymes.
DEAE-dextran Chlorcresol Carbamid
DEAE-Dextran Chlorocresol Urea
Debido a las posibles reacciones adversas graves en los lactantes, el periodo de lactancia se suspenderá durante el tratamiento con Siklos.
Because of the potential for serious adverse reactions in infants, breastfeeding must be discontinued while taking Siklos.
Debrecen H-4042 Ungarn
Debrecen H-4042 Hungary
Debridering af hypertrofisk væv under artroskopi kan være nødvendig hos disse patienter.
Patients may require debridement of the hypertrophic tissue via arthroscopy.
Debut af hypophosphatasi var under 6 måneder hos 4 patienter, mellem 6 måneder og 18 år hos 12 patienter og over 18 år hos 2 patienter.
Onset of hypophosphatasia was under 6 months in 4 patients, between 6 months and 18 years in 12 patients and over 18 years in 2 patients.
Debut i barndommen: Hos patienter med isoleret GHD med debut i barndommen (ingen tegn på hypothalamisk-hypofysær sygdom eller kraniel bestråling), bør to dynamiske tests anbefales, undtagen hos patienter med lave insulinlignende vækstfaktor-I (IGF-I)-koncentrationer (< -2 standardafvigelsesscore (SDS)), som kan komme i betragtning til én test.
Childhood-onset: In patients with childhood-onset isolated GHD (no evidence of hypothalamic-pituitary disease or cranial irradiation), two dynamic tests should be performed after completion of growth, except for those having low insulin-like growth factor-I (IGF-I) concentrations (< -2 standard deviation score (SDS)), who may be considered for one test.
Debutalderen var ikke kendt hos 1 patient.
Age of onset was not known for 1 patient.
Debuterende diabetes mellitus eller hyperglykæmi, eller forværring af allerede eksisterende diabetes mellitus, hypertriglyceridæmi, hyperkolesterolæmi.
new onset diabetes mellitus or hyperglycaemia, or exacerbation of pre-existing diabetes mellitus, hypertriglyceridaemia, hypercholesterolaemia.
Debuterende eller forvæ rring af allerede eksisterende psoriasis, inklusive pustuløs psoriasis (primæ rt palmoplantaris), urticaria, udslæ t, pruritus, øget svedtendens, tør hud, svampedermatitis, eksem, alopeci.
New onset or worsening psoriasis including pustular psoriasis (primarily palm & soles), urticaria, rash, pruritus, hyperhidrosis, dry skin, fungal dermatitis, eczema, alopecia.
Debuterende eller forvæ rring af eksisterende hjertesvigt, langsom hjertefrekvens (puls)
New or worsening heart failure, slow heart rate
Debuterende eller forværring af eksisterende hjertesvigt, langsom hjertefrekvens (puls)
New or worsening heart failure, slow heart rate
December 2013
December 2018
December 2017
1: December
December 2018.
December 2018
Dechra Veterinary Products BV Pettelaarpark 38
Orion Pharma Kubiliaus str.6
Decitabin har vist sig at være en svag hæmmer af P-gp-medieret transport in vitro og forventes derfor heller ikke at påvirke P-gp-medieret transport af co administrerede lægemidler (se pkt.
Decitabine has been shown to be a weak inhibitor of P-gp mediated transport in vitro and is therefore also not expected to affect P-gp mediated transport of co-administered medicinal products (see section 5.2).
Decitabins farmakokinetik efter intravenøs administration over 1 time blev beskrevet ved hjælp af en lineær 3-kompartmentmodel kendetegnet ved hurtig elimination af lægemidlet fra det centrale kompartment og ved relativt langsom distribution fra det perifere kompartment.
The pharmacokinetics of decitabine following intravenous administration as a 1-hour infusion were described by a linear two-compartment model, characterised by rapid elimination of the drug from the central compartment and by relatively slow distribution from the peripheral compartment.
Decitabins Vdss hos cancerpatienter indikerer hovedsageligt, at stoffet distribueres ind i perifere væv.
Decitabine Vdss in cancer patients is large indicating distribution of the drug into peripheral tissues.
Decitabins virkning på co-administrerede lægemidler
Impact of decitabine on co-administered medicinal products
defekt fedtmetabolisme,
defective metabolism of fat,
Deferasiox’ absolutte biotilgængelighed (AUC) (dispergible tabletter) er omkring 70% sammenlignet med en intravenøs dosis.
The absolute bioavailability (AUC) of deferasirox (dispersible tablet formulation) is about 70% compared to an intravenous dose.
Deferasirox (anvedes til at mindske kronisk jernoverskud)
Deferasirox (used to reduce chronic iron overload)
Deferasirox (anvedes til at mindske kronisk jernoverskud)
Deferasirox (used to reduce chronic iron overload).
Deferasirox (dispergibel tablet-formulering) bliver absorberet efter oral administration med en mediantid til maximum plasmakoncentration (tmax) på omkring 1,5 til 4 timer.
Deferasirox (dispersible tablet formulation) is absorbed following oral administration with a median time to maximum plasma concentration (tmax) of about 1.5 to 4 hours.
Deferasirox dipergible tabletter blev vurderet i et 1-årigt randomiseret, dobbeltblindet, placebokontrolleret studie hos patienter med ikke-transfusionsafhængige thalassæmi-syndromer og jernophobning.
In patients with non-transfusion-dependent thalassaemia syndromes and iron overload, treatment with deferasirox dispersible tablets was assessed in a 1-year, randomised, double-blind, placebo-controlled study.
Deferasirox dispergible tabletter blev vurderet i et 1-årigt randomiseret, dobbeltblindet, placebokontrolleret studie hos patienter med ikke-transfusionsafhængige thalassæmi-syndromer og jernophobning.
In patients with non-transfusion-dependent thalassaemia syndromes and iron overload, treatment with deferasirox dispersible tablets was assessed in a 1-year, randomised, double-blind, placebo-controlled study.
Deferasirox er undersøgt hos 411 voksne (alder ≥ 16 år) og 292 pædiatriske patienter (alder 2 til
Deferasirox has been investigated in 411 adult (age 16 years) and 292 paediatric patients (aged 2 to
Deferasirox fås også som ”filmovertrukne” tabletter.
Deferasirox also comes as “film-coated” tablets.
Deferasiroxmetabolisme afhænger af UGT-enzymer.
Deferasirox metabolism depends on UGT enzymes.
Deferipron
Deferiprone
Defibrotid er derudover in vitro påvist at øge aktiviteten af vævstypeplasminogenaktivator (t-PA) og nedsætte aktiviteten af plasminogenaktivator-inhibitor-1 (PAI-1), resulterende i mindre prokoagulant aktivitet og øget fibrinolytisk potentiale af endotelcellerne.
Also, in vitro, defibrotide has been shown to increase tissue-type plasminogen activator (t-PA) function and decrease plasminogen activator inhibitor-1 (PAI-1) activity resulting in a decrease in procoagulant activity and an increase in the fibrinolytic potential of endothelial cells.
Defibrotid er desuden påvist at beskytte endotelcellerne mod fludarabin- medieret apoptose uden at påvirke dets antileukæmiske virkning.
Defibrotide has also been shown to protect endothelial cells from fludarabine-mediated apoptosis, while not impacting its anti-leukemic effect.
Defibrotid er desuden påvist at have svag profibrinolytisk aktivitet in vitro.
Defibrotide also has been shown to have a weak profibrinolytic activity in vitro.
Defibrotid er in vitro påvist at bindes til det vaskulære endotel på forskellige bindingssteder, som er involveret i cellernes regulering, hvorved det fremkalder et stimulus, der fremmer beskyttelsen af aktiverede endotelceller.
In vitro, defibrotide has been shown to bind to various sites on vascular endothelium that are involved in cell regulation, providing a stimulus that promotes protection of activated endothelial cells.
Defibrotid hæmmer endvidere ekspressionen af heparanase, hvilket bidrager til integriteten af den ekstracellulære matrix og dermed til homøostasen i vævene.
Defibrotide also inhibits the expression of heparanase contributing to extracellular matrix integrity and thereby tissue homeostasis.
Deficitter i skeletal ossifikation blev observeret adskillige steder i hunrottefostre, som fik sevelamer i middelstore og høje doser (tilsvarende dosis for mennesker var mindre end den maksimale dosis på 14,4 g i det kliniske studie).
Deficits in skeletal ossification were observed in several locations in foetuses of female rats dosed with sevelamer at intermediate and high doses (human equivalent dose less than the maximum clinical trial dose of 14.4 g).
Deficitter i skeletal ossifikation blev observeret adskillige steder i hunrottefostre, som fik sevelamer i middelstore og høje doser (tilsvarende dosis for mennesker var mindre end den maksimale dosis på 14,4 g i det kliniske studier).
Deficits in skeletal ossification were observed in several locations in foetuses of female rats dosed with sevelamer at intermediate and high doses (human equivalent dose less than the maximum clinical trial dose of 14.4 g).
DEFINE
(0.21, 0.41)
DEFINE
0.169
Defineret som et ≤0,1 % forhold af BCR-ABL til ABL-transkripter på den internationale skala (IS) (dvs. ≤0,1 % BCR-ABLIS; patienter skal have b2a2/b3a2- (p210) transkriptet), i perifert blod målt ved kvantativ revers-transkriptase-polymerase-kædereaktion (qRT PCR).
Defined as a ≤0.1% ratio of BCR-ABL to ABL transcripts on the International Scale (IS) (ie, ≤0.1% BCR-ABLIS; patients must have the b2a2/b3a2 (p210) transcript), in peripheral blood measured by quantitative reverse transcriptase polymerase chain reaction (qRT PCR).
defineret som fravær af hvilken som helst invasiv kræft både i bryst og aksilknuder
defined as absence of any invasive cancer both in the breast and axillary nodes
Defineret som HCV RNA under detektionsgrænsen ved brug af en forskningsbaseret RT-PCR analyse ved afslutningen af behandlingen og i opfølgningsperioden
Defined as HCV-RNA below limit of detection using a research based RT-PCR assay at end of treatment and during follow-up period.
Defineret som HCV RNA under detektionsgrænsen ved brug af en forskningsbaseret RT-PCR analyse ved afslutningen af behandlingen og under opfølgningsperioden
Defined as HCV-RNA below limit of detection using a research based RT-PCR assay at end of treatment and during follow-up period.
Defineret som HCV-RNA under detektionsgrænsen ved brug af en forskningsbaseret RT-PCR-analyse ved afslutningen af behandlingen og under opfølgningsperioden
Defined as HCV-RNA below limit of detection using a research based RT-PCR assay at end of treatment and during follow-up period
Definition af blødningskategorier:
Bleeding category definitions:
Definition af kvinder i den fertile alder (Women of Childbearing Potential (WCBP)) samt hvilke handlinger, den ordinerende læge skal foretage, hvis der er uklarhed om graviditetsstatus
Definition of women of childbearing potential (WCBP) and actions the prescriber should take if childbearing status is unclear
Definition af kvinder i den fertile alder og af de forholdsregler, som lægen skal tage i tvivlstilfælde
Definition of women of childbearing potential (WCBP) and actions the physician should take if unsure
Definition af sikker prævention og nødvendigheden af at søge eksperthjælp, hvis der er usikkerhed om, hvad der er bedst for den enkelte patient.
Definition of reliable contraception and the need to seek expert advice if unsure what is suitable for an individual patient.
Definitionen af alvorlig blødning (major bleeding event, MBE) fulgte anbefalingerne fra the International Society on Thrombosis and Haemostasis, som beskrevet under RE-COVER og RE- COVER II.
The definition of MBEs followed the recommendations of the International Society on Thrombosis and Haemostasis as described under RE-COVER and RE-COVER II.
Definitionen af alvorlig blødning (major bleeding event, MBE) fulgte anbefalingerne fra the International Society on Thrombosis and Haemostasis.
The definition of major bleeding events (MBEs) followed the recommendations of the International Society on Thrombosis and Haemostasis.
Definitionen af bivirkningen alvorlig blødning i RE-NOVATE og RE-MODEL studierne var følgende:
The definition of the adverse reaction major bleeding in the RE-NOVATE and RE-MODEL studies were as follows:
Definitionen af MBE fulgte anbefalingerne fra the International Society on Thrombosis and Haemostasis, som beskrevet under RE-COVER og RE-COVER II.
The definition of MBEs followed the recommendations of the International Society on Thrombosis and Haemostasis as described under RE-COVER and RE-COVER II.
definitiv stenttrombose
Definite stent thrombosis
Defitelio administreres ved intravenøs infusion i løbet af to timer.
Defitelio is administered by intravenous infusion, over two hours.
Defitelio blev påvist at nedsætte dødeligheden til 62 % 100 dage efter transplantationen, og hos 24 % af patienterne var symptomerne på svær VOD fuldstændig forsvundet efter 100 dage.
Defitelio was shown to lower the mortality rate to 62% at 100 days after transplantation, and in 24% of patients the symptoms of severe VOD were completely resolved after 100 days.
Defitelio bør administreres i mindst 21 dage, og behandlingen fortsættes, indtil symptomerne og tegnene på svær VOD svinder.
Defitelio should be administered for a minimum of 21 days and continued until the symptoms and signs of severe VOD resolve.
Defitelio bør ikke anvendes under graviditet, medmindre kvindens kliniske tilstand nødvendiggør behandling med Defitelio.
Defitelio should not be used during pregnancy unless the clinical condition of the woman requires treatment with Defitelio.
Defitelio defibrotid
Defitelio defibrotide
Defitelio er et bleggult til brunt koncentrat til infusionsopløsning og er fri for partikler eller uklarhed.
Defitelio is a clear light yellow to brown concentrate for solution for infusion, free from particulate matter or turbidity.
Defitelio er et lægemiddel, der indeholder det aktive stof defibrotid.
Defitelio is a medicine containing the active substance defibrotide.
Defitelio er godkendt under “særlige omstændigheder”.
Defitelio has been authorised under ‘exceptional circumstances’.
Defitelio er udelukkende til engangsbrug.
Defitelio is for single use only.
Defitelio forventes ikke at påvirke din evne til at føre motorkøretøj og betjene maskiner.
It is not expected that Defitelio will affect your ability to drive and operate machinery.
Defitelio forventes ikke eller kun i ubetydelig grad at påvirke evnen til at føre motorkøretøj eller betjene maskiner.
Defitelio is expected to have no or negligible influence on the ability to drive and operate machinery.
Defitelio fås kun på recept, og behandlingen skal ordineres og gives af en læge med erfaring i behandling af komplikationer til transplantation af bloddannende stamceller.
Defitelio can only be obtained with a prescription and must be prescribed and given by a doctor experienced in the management of complications of haematopoietic stem cell transplantation.
Defitelio gives fire gange dagligt i en dosis af 6,25 mg/kg legemsvægt.
Defitelio is given four times a day at a dose of 6.25 mg per kg body-weight.
Defitelio hverken hæmmer eller inducerer CYP-enzymer.
Defitelio does not inhibit or induce CYP450s.
Defitelio kan anvendes hos voksne og hos børn over en måned gamle.
Defitelio is used in adults and in children from one month of age.
Defitelio kan fortyndes med isoton glukose 5 % til infusion eller isoton natriumchlorid 9 mg/ml (0,9 %) til infusion til en koncentration, der er passende til infusion over 2 timer.
Defitelio can be diluted with 5% glucose solution for infusion or sodium chloride 9 mg/mL (0.9%) solution for infusion, to a suitable concentration to permit infusion over 2 hours.
Defitelio kan som al anden medicin give bivirkninger, men ikke alle får bivirkninger.
Like all medicines, Defitelio can cause side effects, although not everybody gets them.
Defitelio må ikke anvendes sammen med andre lægemidler, der nedbryder blodpropper.
Defitelio must also not be used together with other medicines that break down blood clots.
Defitelio, 80 mg/ml, koncentrat til infusionsvæske, opløsning
Defitelio 80 mg/mL concentrate for solution for infusion
Defitelios sikkerhed og virkning hos børn under 1 måned er endnu ikke klarlagt.
The safety and efficacy of Defitelio in children aged less than 1 month has not yet been established.
Defosforylering fører til dannelse af nukleosidmetabolitten GS-331007, der ikke kan refosforyleres effektivt, og som mangler anti-HCV- aktivitet in vitro.
Dephosphorylation results in the formation of nucleoside metabolite GS-331007 that cannot be efficiently rephosphorylated and lacks anti-HCV activity in vitro.
Degarelix er ikke et substrat for det humane CYP-system og har ikke induceret eller hæmmet CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1 eller CYP3A4/5 i nævneværdig grad in vitro.
Degarelix is not a substrate for the human CYP450 system and has not been shown to induce or inhibit CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, or CYP3A4/5 to any great extent in vitro.
Degarelix er ikke undersøgt hos patienter med stærkt nedsat nyrefunktion, og forsigtighed bør derfor udvises.
Degarelix has not been studied in patients with severe renal impairment and caution is therefore warranted.
Degeneration af det seminiferøse epitel blev forbundet med palonosetron efter et 1- måneds toksicitetsstudie med gentagne orale doser hos rotter.
Degeneration of seminiferous epithelium was associated with palonosetron following a one month oral repeat dose toxicity study in rats.
Degeneration af det seminiferøse epitel er blevet observeret i rottestudier (se pkt.
Degeneration of seminiferous epithelium has been observed in rat study (see section 5.3).
Degraderingsproduktet af Velphoro, mononukleære jernarter, kan dog frigives fra overfladen af polynukleært jern(III)- oxyhydroxid og absorberes.
However, the degradation product of Velphoro, mononuclear iron species, can be released from the surface of polynuclear iron(III)-oxyhydroxide and be absorbed.
DEHP-frit PVC indeholdende trioctyl-trimellitat (TOTM)
DEHP free PVC containing trioctyl-trimellitate (TOTM)
Dehydrering
Common Dehydratation,
dehydrering
dehydration
Dehydrering
dehydration,
Dehydrering
Diarrhoea
Dehydrering (2,8 %) (G3/4: 0,5 %)d
Dehydration (2.8 %) (G3/4: 0.5%)d
Dehydrering (alle grader) er observeret hos 9,0 % af patienterne i ZALTRAP-armen og hos 3,0 % i placeboarmen.
Dehydration (all grades) has been observed in 9.0% of patients treated with ZALTRAP/FOLFIRI and 3.0% of patients treated with placebo/FOLFIRI.
Dehydrering (almindelig) som følge af længerevarende diarré, opkastning, kvalme eller appetitløshed.
Dehydration (common) caused by long term or severe diarrhoea, vomiting (being sick), nausea (feeling sick) or loss of appetite.
Dehydrering (for stort væsketab)
Dehydration (losing too much fluid)
Dehydrering (G3/4: 2 %);
Insomnia
Dehydrering (ikke almindelig - kan berøre op til 1 ud af 100 personer) væsketab fra kroppen.
Dehydration (uncommon, may affect up to 1 in 100 people) loss of too much fluid from your body (dehydration).
Dehydrering (ikke almindelig, kan berøre op til 1 ud af 100 personer) et voldsomt væsketab fra kroppen (dehydrering).
Dehydration (uncommon, may affect up to 1 in 100 people) loss of too much fluid from your body (dehydration).
dehydrering (lavt vand- eller væskeindhold i kroppen)
Dehydration (low levels of water or fluid)
dehydrering (lavt vand- eller væskeniveau i kroppen)
Dehydration (low levels of water or fluid)
Dehydrering (NB), anoreksi (B)
Dehydration (NB), Anorexia (B)